#United States #San Diego #Robbins LLP #class action lawsuit #PepGen Inc.

Investors Alert About Regular Developments: Class Action Lawsuit Against PepGen Inc.

On June 20, 2025, Robbins LLP issued a reminder to PepGen Inc. stockholders, encouraging those who experienced substantial losses to reach out concerning a class action lawsuit. This class action has been filed on behalf of investors who acquired PepGen Inc. (NASDAQ: PEPG) securities from March 7, 2024, to March 3, 2025. For those unfamiliar with the company, PepGen is a clinical-stage biotechnology entity specializing in developing oligonucleotide therapeutics aimed at severe neuromuscular and neurologic diseases. Among their flagship products is PGN-EDO51, a proprietary oligonucleotide peptide intended for treating Duchenne muscular dystrophy (DMD).

Allegations of Misleading Conduct

According to the complaint, there are serious allegations of misconduct by the defendants. The lawsuit asserts that PepGen failed to deliver truthful information regarding the effectiveness and safety of its leading drug, PGN-EDO51. It is notably claimed that they misrepresented data related to their CONNECT2 study, characterized by apparent safety issues that could jeopardize U.S. Food and Drug Administration (FDA) approval. Thus, investor confidence was manipulated, as the true status of clinical, regulatory, and commercial prospects was far less optimistic than presented.

Key allegations include:

• - Ineffective Drug Candidate: Claims that PGN-EDO51 was not as effective and safe as the company had led investors to believe.
• - Flawed Studies: Assertions that the CONNECT2 study harbored safety concerns that were not disclosed and could lead to its suspension.
• - False Statements: Allegations that public communications from the company were misleading, contributing significantly to exaggerated stock valuations.

Recent Developments and Stock Price Reactions

On January 29, 2025, PepGen issued a press release that hinted at emerging safety concerns from the CONNECT1 study, revealing troubling reports about a participant’s health after receiving a certain dosage. Subsequent inquiries from Health Canada added further pressure on the company, as they sought additional information about these safety issues. Following this announcement, PepGen's stock price plummeted by 21.74%, closing at $1.44 per share the following day.

In another revelation on March 4, 2025, PepGen publicly declared a voluntary pause of the CONNECT2 study, justifying this decision as a necessary step to review ongoing studies. This announcement ultimately caused the stock price to drop another 18.86%, settling at $2.28 per share.

How to Get Involved

Investors who believe they might be entitled to participate in the class action against PepGen Inc. are encouraged to act swiftly. Shareholders seeking to be the lead plaintiff in this case must file a motion by August 8, 2025. Importantly, potential plaintiffs do not need to actively engage in the case to qualify for recovery; there’s an option to remain an absent class member.

Robbins LLP operates on a contingency fee basis, meaning shareholders are not required to pay any fees or expenses upfront. Legal representation is contingent upon the successful recovery of losses.

About Robbins LLP

Robbins LLP has been a stalwart in shareholder rights litigation since 2002, committed to securing recovery for affected investors and striving to enhance corporate governance practices for holding company executives accountable.

For more insights on the ongoing class action lawsuit against PepGen, to receive updates about the case's settlement, or alerts about when corporate misconduct arises, interested parties can register for the Stock Watch service.

Attorney Advertising: Please note that past outcomes are not guaranteed to produce similar results in future cases.